Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA), Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), Prof Nicolas Mottet (University Hospital St Etienne, St Etienne, France) and Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) discuss the updates from ESMO 2021 in hormone-sensitive prostate cancer.
Initially, they discuss the latest developments in therapies for hormone-sensitive prostate cancer presented at ESMO 2021.
They talk about the final overall survival (OS) analysis from ARCHES, STAMPEDE and PEACE-1 trial.
Dr Castro and Prof Efstathiou further talk about the role of imaging and molecular pathology in treatment choice. They mention the prevalence and clinical impact of PTEN status in patients with de novo metastatic hormone sensitive prostate cancer.
Dr Castro also talks about TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer.
Prof Efstathiou then concludes with a final comment regarding the future.
|PTEN status TMPRSS2-ERG expression in patients with mHSPC|
This programme is supported by an unrestricted educational grant from Janssen.